CNRMF (China Regenerative Medicine International) Tax Provision: $1.59 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CNRMF China Regenerative Medicine International Ltd CNRMF
30 GF Score
Price $0.04
GF Value $0.09
! 5 Warning Signs
View Full Analysis

What is China Regenerative Medicine International Tax Provision?

China Regenerative Medicine International CNRMF 30 Tax Provision is $1.59 Mil as of Dec. 2025. GuruFocus rates CNRMF with a GF Score™ of 30/100 and a GF Value™ of $0.09. The stock has 5 warning signs investors should review.

China Regenerative Medicine International's tax provision for the six months ended in Dec. 2025 was $1.59 Mil. Its tax provision for the trailing twelve months (TTM) ended in Dec. 2025 was $1.59 Mil.

China Regenerative Medicine International Tax Provision Historical Data

* Premium members only.

The historical data trend for China Regenerative Medicine International's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

China Regenerative Medicine International Tax Provision Chart

China Regenerative Medicine International Annual Data
Trend Apr16 Apr17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Tax Provision
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.60 -0.48 0.00 0.00 1.59

China Regenerative Medicine International Semi-Annual Data
Apr16 Oct16 Apr17 Oct17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Tax Provision Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.24 0.00 0.00 0.00 1.59
CNRMF
30GF Score
China Regenerative Medicine International Ltd CNRMF
Tax Provision is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

China Regenerative Medicine International Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $1.59 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Provision →
What does a Tax Provision of $1.59 Mil mean?
China Regenerative Medicine International (CNRMF) has a Tax Provision of $1.59 Mil as of Dec. 2025. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on China Regenerative Medicine International and its competitors.
Is China Regenerative Medicine International's Tax Provision too high?
China Regenerative Medicine International's current Tax Provision is $1.59 Mil. Overall, China Regenerative Medicine International has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does China Regenerative Medicine International's Tax Provision compare to VRTX and REGN?
China Regenerative Medicine International's Tax Provision of $1.59 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Provision for a Biotechnology company?
A good Tax Provision depends on the Biotechnology industry context. However, Tax Provision should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Provision mean?
A high Tax Provision can signal that a stock is expensive relative to its fundamentals. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on China Regenerative Medicine International and its competitors. China Regenerative Medicine International's current Tax Provision is $1.59 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Regenerative Medicine International stock overvalued right now?
China Regenerative Medicine International (CNRMF) has a current Tax Provision of $1.59 Mil. The stock's GF Value™ is $0.09, compared to a current price of $0.04 — trading 61.1% below its estimated fair value. The current Tax Provision is $1.59 Mil. China Regenerative Medicine International's overall GF Score™ is 30/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Provision calculated?
Tax Provision is calculated from a company's financial statements. For China Regenerative Medicine International (CNRMF), the current Tax Provision is $1.59 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is China Regenerative Medicine International (CNRMF) Overvalued in 2026?

Based on GuruFocus' analysis, China Regenerative Medicine International stock appears to be undervalued. The current stock price of $0.04 is trading 61.1% below its estimated GF Value™ of $0.09.

Key valuation signals for CNRMF:

  • Tax Provision: $1.59 Mil
  • GF Value™: $0.09 vs. price of $0.04 (61.1% below fair value)
  • GF Score™: 30/100 with 5 warning signs

No single metric tells the full story. See the CNRMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

China Regenerative Medicine International Business Description

Other Exchanges 08158:Hong Kong
Address 132 Nathan Road, Suite 2310-2318, Miramar Tower, Tsim Sha Tsui, Kowloon, HKG
China Regenerative Medicine International Ltd is an investment holding company. The company is engaged in the provision of healthcare products and services. It is engaged in research and development, production and sales of tissue engineering and regenerative medicine products. The business scope of company includes tissue engineering, cosmetics, cell storage, preparation and therapy, hospitals administration and other business division. The segments of the company are Aesthetic medical and beauty services and Medical services. The majority of the company's revenue is derived from its Aesthetic medical and beauty services segment that provides medical beauty products and services. Geographically, the Hong Kong accounts for the majority of the revenue and also has a presence in PRC.
30GF Score

Get the complete analysis for CNRMF

Tax Provision is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.04
Price
$0.09
GF Value